213055 “Research Priorities Relevant to FDA Legislation to Regulate Tobacco Products”

Monday, November 9, 2009: 5:20 PM

K. Michael Cummings, PhD MPH , Department of Health Behavior, Roswell Park Cancer Institute, Buffalo, NY
Cathy L. Backinger, PhD, MPH , Tobacco Control Research Branch, National Cancer Institute, Bethesda, MD
Dorothy K. Hatsukami, PhD , Transdisciplinary Tobacco Use Research Center, University of Minnesota, Minneapolis, MN
Scott Leischow , University of Arizona, Baltimore, AZ
Mitch Zeller, JD , Pinney Associates, Bethesda, MD
  
In March 2009, the National Cancer Institute commissioned a series of white papers to identify research needs related to the then-pending legislation to regulate tobacco products. To effectively allocate limited research funds and make informed decisions that will impact future public health policy, a scientific literature review was undertaken by experts in the field of nicotine and tobacco research to help develop research priorities. This presentation will summarize highlights from these seven papers. Each paper addresses what the current regulation provides, regulation history (if applicable), what is known, and research opportunities. Topics include: Product Standards, Product Testing, Product Marketing and Sales, Labeling, Disclosures, Post-market Surveillance, and Youth Tobacco Use. Research opportunities identified through this project will be important to consider as FDA implements this legislation and time will be provided to discuss research opportunities and priorities. Potential funding opportunities will also be discussed.

Learning Objectives:
Discuss unanswered research questions that will inform the process of effectively regulating tobacco products, Describe a framework for these areas of research to stimulate further thinking about these crucial topics.

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: Unique experience on this subject.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.

See more of: FDA Regulation of Tobacco Products: What it Means for Policy, Practice and Research
See more of: Alcohol, Tobacco, and Other Drugs